![](https://endpts.com/wp-content/uploads/2023/02/Christopher-Anzalone-Arrowhead-tile.jpg)
Christopher Anzalone, Arrowhead Pharmaceuticals CEO
After Phase 3 win, Arrowhead's RNAi chases Ionis to market entry in rare genetic disorder
Arrowhead Pharmaceuticals’ RNAi treatment has succeeded in a registrational test in patients with an ultra-rare lipid metabolism disorder, bolstering plans for a regulatory filing that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.